热门资讯> 正文
Rani Therapeutics首席财务官桑福德将离职
2026-05-16 05:00
- Rani Therapeutics (RANI) said on Friday that chief financial officer Svai Sanford will leave the company after a successor is appointed, as the company announced a series of leadership changes and operational updates.
- Sanford, who helped lead Rani through its initial public offering and financing initiatives, will remain during a transition period to support an orderly handover, the company said.
- Rani said in its first quarter, co promoted Alireza Javadi to chief technical officer, appointed Jesper Høiland as head of strategy and named Sara Kenkare-Mitra as a strategic advisor.
- Stock down -2% in aftermarket trading after Rani posted Q1 GAAP EPS of -$0.04 in-line. Contract revenue of $1.7M (+900.0% Y/Y) beats by $1.2M.
More on Rani Therapeutics
- Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript
- Rani Therapeutics GAAP EPS of -$0.04 in-line, revenue of $1.7M beats by $1.2M
- Seeking Alpha’s Quant Rating on Rani Therapeutics
- Historical earnings data for Rani Therapeutics
- Financial information for Rani Therapeutics
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。